Resistance Markers Are Common Across Plasmodium vivax Samples in Southwestern India

The genetic fingerprint of Plasmodium vivax in southwestern India already shows substantial pressure on the standard treatment backbone of chloroquine followed by 14 days of primaquine. In 93 clinical samples drawn from symptomatic adults across three sites in two districts, resistance-associated polymorphisms appeared repeatedly in the parasite genes most often tracked for antimalarial escape. The pattern does not prove uniform clinical failure of chloroquine, but it does show a parasite population carrying multiple mutations that have long been watched as warning signs for reduced drug susceptibility.

This is the kind of molecular signal that matters before treatment failure becomes obvious at the bedside.

The samples came from Kasturba Medical College in Manipal, Udupi District Hospital, and Mangaluru District Hospital over a collection window extending from mid-2021 through late 2024. DNA extracted from these clinical specimens underwent Sanger sequencing for four loci central to resistance surveillance: Pvcrt-o, Pvmdr1, Pvdhfr, and Pvdhps. Each of these genes maps onto a different arm of the parasite’s adaptive response, from chloroquine transport and intracellular handling to folate pathway pressure from antifolate drugs. The result is not a single-mutation story. It is a layered resistance profile.

Chloroquine-Linked Loci Show a Mixed but Concerning Pattern

Within Pvcrt-o, the K10 AAG insertion appeared in 26% of samples. That change is of interest because Pvcrt-o has long been studied as a candidate determinant in chloroquine response, with altered transporter function offering a plausible route for the parasite to blunt intracellular drug effect. On its own, the insertion cannot be read as proof of therapeutic failure, but its presence in more than one-quarter of the cohort shows that a recognized resistance-associated signature is circulating in the local parasite population.

The Pvmdr1 gene carried an even broader set of mutations. M908L was present in 100% of samples, T958M in 86.02%, Y976F in 2.15%, and F1076L in 84.94%. A parasite population with nearly universal M908L and very high rates of T958M and F1076L is not genetically static; it is under selection. Pvmdr1 encodes a transporter implicated in multidrug handling, and combinations of substitutions at this locus have repeatedly drawn attention in chloroquine-exposed settings. The most clinically sensitive finding in the series was the rare Y976F mutation, identified in two samples. Prior work has associated that variant with reduced chloroquine susceptibility, making its appearance especially important even at low frequency.

Folate Pathway Mutations Suggest Additional Drug Pressure

The folate pathway markers added another layer. Pvdhfr showed S58R in 59.13% of samples and S117N in 56.98%, with the double mutant S58R plus S117N emerging as the most prevalent haplotype. Those substitutions are classically linked to antifolate resistance and reflect the parasite’s capacity to survive under drug pressure aimed at folate metabolism. In practical terms, the dominance of the double mutant means the circulating parasite pool has already accumulated a combination that can diminish susceptibility in the pathway targeted by related antimalarial compounds.

Changes in Pvdhps were also present, with A383G in 26.88% and A553G in 13.97% of samples. Because Pvdhfr and Pvdhps function together in folate biosynthesis, resistance markers in both genes are more informative than either gene alone. Their co-occurrence signals cumulative selection pressure and strengthens the case for ongoing molecular monitoring rather than reliance on a single surveillance point.

Why These Mutations Matter at the Bedside

Molecular surveillance does not replace clinical outcome data, but it often detects trouble before fever patterns and parasitemia clearance times make the problem obvious. In P. vivax, treatment decisions are complicated further by relapse biology, hypnozoite persistence, and the need for primaquine to address dormant liver stages. When resistance-associated polymorphisms accumulate in the bloodstream parasite population, clinicians lose some of the confidence that standard regimens will behave predictably across all transmission settings.

The current findings fit a familiar malaria principle: resistance rarely arrives as a single dramatic switch. It builds through a series of small genetic changes, some widespread, some rare, each carrying different weight in the clinic. A mutation such as Y976F may be uncommon, but its presence in a region where chloroquine remains the recommended first-line treatment deserves attention because rare variants can expand under sustained drug exposure. The broader set of Pvmdr1 substitutions suggests that the local parasite population is already well adapted to antimalarial pressure, even if not all mutations translate into the same level of phenotypic resistance.

A Surveillance Signal, Not a Clinical Endpoint

These data do not establish complete chloroquine resistance in southwestern India, and they do not provide direct treatment-failure rates. They do, however, establish that the parasite population carries several mutations repeatedly linked to antimalarial resistance and that one chloroquine-associated variant of particular concern was detected in a small subset of samples. For malaria programs, that is enough to justify closer monitoring.

The study supports a strategy built on repeated genotyping, site-level comparison, and linkage of molecular findings to clinical response whenever possible. In settings where chloroquine remains standard therapy for Plasmodium vivax, surveillance can no longer be treated as an academic exercise. It is part of maintaining drug efficacy. Continued sampling across districts, paired with clinical follow-up and parasitologic response data, will be needed to determine whether these resistance markers remain sporadic or begin to shift toward a pattern that should change treatment policy.


Reporting by Dr. A.R. Athira, MBBS for Medicine World Foundation, with additional data provided by PLOS Medicine.
PRIMARY CLINICAL EVIDENCE & REGISTRY DATA